nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CHEK2—peripheral nervous system neoplasm	0.447	0.892	CbGaD
Gefitinib—ABCB1—peripheral nervous system neoplasm	0.0543	0.108	CbGaD
Gefitinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0343	0.118	CbGbCtD
Gefitinib—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0294	0.101	CbGbCtD
Gefitinib—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0253	0.087	CbGbCtD
Gefitinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0238	0.0817	CbGbCtD
Gefitinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0177	0.0607	CbGbCtD
Gefitinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0146	0.0503	CbGbCtD
Gefitinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0137	0.0469	CbGbCtD
Gefitinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0134	0.0461	CbGbCtD
Gefitinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0124	0.0425	CbGbCtD
Gefitinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0124	0.0425	CbGbCtD
Gefitinib—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0119	0.0407	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00915	0.0315	CbGbCtD
Gefitinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00858	0.0295	CbGbCtD
Gefitinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.00811	0.0279	CbGbCtD
Gefitinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00744	0.0256	CbGbCtD
Gefitinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00741	0.0255	CbGbCtD
Gefitinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00689	0.0237	CbGbCtD
Gefitinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00528	0.0181	CbGbCtD
Gefitinib—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00508	0.0174	CbGbCtD
Gefitinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00493	0.0169	CbGbCtD
Gefitinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00484	0.0166	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0033	0.0113	CbGbCtD
Gefitinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00316	0.0109	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00311	0.0107	CbGbCtD
Gefitinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0029	0.00996	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00198	0.0068	CbGbCtD
Gefitinib—Lapatinib—ERBB2—peripheral nervous system neoplasm	0.00181	0.362	CrCbGaD
Gefitinib—Afatinib—ERBB2—peripheral nervous system neoplasm	0.00129	0.257	CrCbGaD
Gefitinib—Bosutinib—CHEK2—peripheral nervous system neoplasm	0.000662	0.132	CrCbGaD
Gefitinib—Bosutinib—ALK—peripheral nervous system neoplasm	0.00059	0.118	CrCbGaD
Gefitinib—CHEK2—Vindesine—Vincristine—peripheral nervous system neoplasm	0.000529	0.181	CbGdCrCtD
Gefitinib—ERBB3—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000494	0.169	CbGdCrCtD
Gefitinib—SBK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000466	0.107	CbGeAlD
Gefitinib—ERBB3—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.00034	0.116	CbGdCrCtD
Gefitinib—CHEK2—Vinorelbine—Vincristine—peripheral nervous system neoplasm	0.000334	0.114	CbGdCrCtD
Gefitinib—CHEK2—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000334	0.114	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000334	0.114	CbGdCrCtD
Gefitinib—Lapatinib—ABCB1—peripheral nervous system neoplasm	0.000261	0.0521	CrCbGaD
Gefitinib—CSNK1E—trigeminal ganglion—peripheral nervous system neoplasm	0.000257	0.0591	CbGeAlD
Gefitinib—IRAK4—trigeminal ganglion—peripheral nervous system neoplasm	0.000253	0.0582	CbGeAlD
Gefitinib—CSNK1E—parotid gland—peripheral nervous system neoplasm	0.000243	0.0558	CbGeAlD
Gefitinib—IRAK4—parotid gland—peripheral nervous system neoplasm	0.000239	0.0549	CbGeAlD
Gefitinib—MKNK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000236	0.0543	CbGeAlD
Gefitinib—MKNK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000233	0.0536	CbGeAlD
Gefitinib—CHEK2—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.00023	0.0784	CbGdCrCtD
Gefitinib—MKNK2—parotid gland—peripheral nervous system neoplasm	0.000223	0.0512	CbGeAlD
Gefitinib—SBK1—cerebellum—peripheral nervous system neoplasm	0.000203	0.0467	CbGeAlD
Gefitinib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.000192	0.0441	CbGeAlD
Gefitinib—Afatinib—ABCB1—peripheral nervous system neoplasm	0.000185	0.0369	CrCbGaD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000174	0.0594	CbGdCrCtD
Gefitinib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000171	0.0394	CbGeAlD
Gefitinib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000162	0.0372	CbGeAlD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.055	CbGdCrCtD
Gefitinib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.000152	0.0349	CbGeAlD
Gefitinib—Erlotinib—ABCB1—peripheral nervous system neoplasm	0.000131	0.0261	CrCbGaD
Gefitinib—EGFR—cerebellum—peripheral nervous system neoplasm	0.000117	0.0268	CbGeAlD
Gefitinib—CSNK1E—cerebellum—peripheral nervous system neoplasm	0.000112	0.0258	CbGeAlD
Gefitinib—IRAK4—cerebellum—peripheral nervous system neoplasm	0.000111	0.0254	CbGeAlD
Gefitinib—ERBB3—cerebellum—peripheral nervous system neoplasm	0.000108	0.0249	CbGeAlD
Gefitinib—MKNK2—cerebellum—peripheral nervous system neoplasm	0.000103	0.0237	CbGeAlD
Gefitinib—IRAK1—cerebellum—peripheral nervous system neoplasm	0.000103	0.0237	CbGeAlD
Gefitinib—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000102	0.000789	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000788	CcSEcCtD
Gefitinib—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000102	0.000788	CcSEcCtD
Gefitinib—Malaise—Cisplatin—peripheral nervous system neoplasm	0.000102	0.000786	CcSEcCtD
Gefitinib—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000102	0.000786	CcSEcCtD
Gefitinib—MKNK1—cerebellum—peripheral nervous system neoplasm	0.000102	0.0234	CbGeAlD
Gefitinib—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000102	0.000783	CcSEcCtD
Gefitinib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000101	0.00078	CcSEcCtD
Gefitinib—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000101	0.00078	CcSEcCtD
Gefitinib—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000101	0.00078	CcSEcCtD
Gefitinib—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000101	0.00078	CcSEcCtD
Gefitinib—Dermatitis bullous—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000778	CcSEcCtD
Gefitinib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000101	0.000777	CcSEcCtD
Gefitinib—Pain—Dactinomycin—peripheral nervous system neoplasm	9.99e-05	0.00077	CcSEcCtD
Gefitinib—Pruritus—Melphalan—peripheral nervous system neoplasm	9.98e-05	0.00077	CcSEcCtD
Gefitinib—Anorexia—Vincristine—peripheral nervous system neoplasm	9.94e-05	0.000767	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—peripheral nervous system neoplasm	9.92e-05	0.000766	CcSEcCtD
Gefitinib—Eye pain—Doxorubicin—peripheral nervous system neoplasm	9.88e-05	0.000762	CcSEcCtD
Gefitinib—Diarrhoea—Topotecan—peripheral nervous system neoplasm	9.85e-05	0.00076	CcSEcCtD
Gefitinib—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	9.77e-05	0.000754	CcSEcCtD
Gefitinib—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	9.77e-05	0.000754	CcSEcCtD
Gefitinib—Hypotension—Vincristine—peripheral nervous system neoplasm	9.75e-05	0.000752	CcSEcCtD
Gefitinib—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	9.65e-05	0.000745	CcSEcCtD
Gefitinib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	9.65e-05	0.000744	CcSEcCtD
Gefitinib—Anaemia—Etoposide—peripheral nervous system neoplasm	9.57e-05	0.000738	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	9.56e-05	0.000737	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	9.55e-05	0.000737	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Doxorubicin—peripheral nervous system neoplasm	9.45e-05	0.000729	CcSEcCtD
Gefitinib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	9.41e-05	0.000726	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	9.35e-05	0.000721	CcSEcCtD
Gefitinib—Malaise—Etoposide—peripheral nervous system neoplasm	9.34e-05	0.00072	CcSEcCtD
Gefitinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	9.33e-05	0.00072	CcSEcCtD
Gefitinib—Dermatitis bullous—Doxorubicin—peripheral nervous system neoplasm	9.33e-05	0.00072	CcSEcCtD
Gefitinib—Pain—Alitretinoin—peripheral nervous system neoplasm	9.26e-05	0.000714	CcSEcCtD
Gefitinib—Constipation—Alitretinoin—peripheral nervous system neoplasm	9.26e-05	0.000714	CcSEcCtD
Gefitinib—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	9.23e-05	0.000712	CcSEcCtD
Gefitinib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	9.23e-05	0.000712	CcSEcCtD
Gefitinib—Infection—Cisplatin—peripheral nervous system neoplasm	9.16e-05	0.000707	CcSEcCtD
Gefitinib—Vomiting—Topotecan—peripheral nervous system neoplasm	9.16e-05	0.000706	CcSEcCtD
Gefitinib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	9.08e-05	0.000701	CcSEcCtD
Gefitinib—Vomiting—Tretinoin—peripheral nervous system neoplasm	9.08e-05	0.000701	CcSEcCtD
Gefitinib—Rash—Topotecan—peripheral nervous system neoplasm	9.08e-05	0.0007	CcSEcCtD
Gefitinib—Dermatitis—Topotecan—peripheral nervous system neoplasm	9.07e-05	0.0007	CcSEcCtD
Gefitinib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	9.07e-05	0.0007	CcSEcCtD
Gefitinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	9.05e-05	0.000698	CcSEcCtD
Gefitinib—Cough—Etoposide—peripheral nervous system neoplasm	9.04e-05	0.000697	CcSEcCtD
Gefitinib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	9.03e-05	0.000697	CcSEcCtD
Gefitinib—Rash—Isotretinoin—peripheral nervous system neoplasm	9.01e-05	0.000695	CcSEcCtD
Gefitinib—Rash—Tretinoin—peripheral nervous system neoplasm	9.01e-05	0.000695	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	9.01e-05	0.000695	CcSEcCtD
Gefitinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	9e-05	0.000694	CcSEcCtD
Gefitinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	9e-05	0.000694	CcSEcCtD
Gefitinib—Fatigue—Vincristine—peripheral nervous system neoplasm	8.99e-05	0.000694	CcSEcCtD
Gefitinib—Vomiting—Melphalan—peripheral nervous system neoplasm	8.97e-05	0.000692	CcSEcCtD
Gefitinib—Dehydration—Epirubicin—peripheral nervous system neoplasm	8.96e-05	0.000691	CcSEcCtD
Gefitinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	8.96e-05	0.000691	CcSEcCtD
Gefitinib—Constipation—Vincristine—peripheral nervous system neoplasm	8.92e-05	0.000688	CcSEcCtD
Gefitinib—Pain—Vincristine—peripheral nervous system neoplasm	8.92e-05	0.000688	CcSEcCtD
Gefitinib—Rash—Melphalan—peripheral nervous system neoplasm	8.89e-05	0.000686	CcSEcCtD
Gefitinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	8.88e-05	0.000685	CcSEcCtD
Gefitinib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	8.85e-05	0.000683	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.000682	CcSEcCtD
Gefitinib—Anorexia—Cisplatin—peripheral nervous system neoplasm	8.79e-05	0.000678	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	8.77e-05	0.000677	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	8.76e-05	0.000675	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	8.68e-05	0.00067	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	8.68e-05	0.00067	CcSEcCtD
Gefitinib—Hypotension—Cisplatin—peripheral nervous system neoplasm	8.62e-05	0.000665	CcSEcCtD
Gefitinib—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	8.6e-05	0.000664	CcSEcCtD
Gefitinib—Urticaria—Alitretinoin—peripheral nervous system neoplasm	8.6e-05	0.000664	CcSEcCtD
Gefitinib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	8.56e-05	0.00066	CcSEcCtD
Gefitinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	8.56e-05	0.00066	CcSEcCtD
Gefitinib—Nausea—Topotecan—peripheral nervous system neoplasm	8.55e-05	0.00066	CcSEcCtD
Gefitinib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	8.53e-05	0.000658	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	8.5e-05	0.000656	CcSEcCtD
Gefitinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	8.49e-05	0.000655	CcSEcCtD
Gefitinib—Nausea—Tretinoin—peripheral nervous system neoplasm	8.49e-05	0.000655	CcSEcCtD
Gefitinib—Infection—Etoposide—peripheral nervous system neoplasm	8.4e-05	0.000648	CcSEcCtD
Gefitinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	8.38e-05	0.000646	CcSEcCtD
Gefitinib—Nausea—Melphalan—peripheral nervous system neoplasm	8.38e-05	0.000646	CcSEcCtD
Gefitinib—STK10—cerebellum—peripheral nervous system neoplasm	8.37e-05	0.0192	CbGeAlD
Gefitinib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	8.34e-05	0.0192	CbGeAlD
Gefitinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	8.29e-05	0.00064	CcSEcCtD
Gefitinib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	8.27e-05	0.000638	CcSEcCtD
Gefitinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	8.25e-05	0.000636	CcSEcCtD
Gefitinib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	8.25e-05	0.000636	CcSEcCtD
Gefitinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	8.22e-05	0.000634	CcSEcCtD
Gefitinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	8.21e-05	0.000633	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000631	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	8.17e-05	0.00063	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	8.12e-05	0.000626	CcSEcCtD
Gefitinib—Anorexia—Etoposide—peripheral nervous system neoplasm	8.06e-05	0.000621	CcSEcCtD
Gefitinib—Bosutinib—ABCB1—peripheral nervous system neoplasm	8.05e-05	0.0161	CrCbGaD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.03e-05	0.00062	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	8.03e-05	0.00062	CcSEcCtD
Gefitinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	8.02e-05	0.000619	CcSEcCtD
Gefitinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	7.99e-05	0.000616	CcSEcCtD
Gefitinib—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	7.98e-05	0.000615	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	7.96e-05	0.000614	CcSEcCtD
Gefitinib—Hypotension—Etoposide—peripheral nervous system neoplasm	7.9e-05	0.000609	CcSEcCtD
Gefitinib—Pain—Cisplatin—peripheral nervous system neoplasm	7.89e-05	0.000609	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	7.87e-05	0.000607	CcSEcCtD
Gefitinib—ABCG2—parotid gland—peripheral nervous system neoplasm	7.87e-05	0.0181	CbGeAlD
Gefitinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	7.77e-05	0.000599	CcSEcCtD
Gefitinib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	7.69e-05	0.000593	CcSEcCtD
Gefitinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	7.66e-05	0.000591	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	7.56e-05	0.000583	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	7.54e-05	0.000581	CcSEcCtD
Gefitinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	7.53e-05	0.000581	CcSEcCtD
Gefitinib—Asthenia—Vincristine—peripheral nervous system neoplasm	7.49e-05	0.000577	CcSEcCtD
Gefitinib—MAP2K5—cerebellum—peripheral nervous system neoplasm	7.48e-05	0.0172	CbGeAlD
Gefitinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	7.47e-05	0.000576	CcSEcCtD
Gefitinib—CYP1A1—parotid gland—peripheral nervous system neoplasm	7.47e-05	0.0172	CbGeAlD
Gefitinib—Infestation—Epirubicin—peripheral nervous system neoplasm	7.43e-05	0.000573	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	7.43e-05	0.000573	CcSEcCtD
Gefitinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	7.42e-05	0.000573	CcSEcCtD
Gefitinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	7.41e-05	0.000571	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	7.36e-05	0.000568	CcSEcCtD
Gefitinib—Rash—Dactinomycin—peripheral nervous system neoplasm	7.36e-05	0.000568	CcSEcCtD
Gefitinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	7.35e-05	0.000567	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	7.3e-05	0.000563	CcSEcCtD
Gefitinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	7.29e-05	0.000563	CcSEcCtD
Gefitinib—Fatigue—Etoposide—peripheral nervous system neoplasm	7.29e-05	0.000562	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	7.24e-05	0.000559	CcSEcCtD
Gefitinib—Pain—Etoposide—peripheral nervous system neoplasm	7.23e-05	0.000558	CcSEcCtD
Gefitinib—Constipation—Etoposide—peripheral nervous system neoplasm	7.23e-05	0.000558	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	7.22e-05	0.000557	CcSEcCtD
Gefitinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	7.14e-05	0.000551	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—peripheral nervous system neoplasm	7.08e-05	0.000546	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	7.02e-05	0.000542	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	7.01e-05	0.00054	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	6.97e-05	0.000538	CcSEcCtD
Gefitinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	6.94e-05	0.000535	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	6.91e-05	0.000533	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	6.91e-05	0.000533	CcSEcCtD
Gefitinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	6.88e-05	0.000531	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	6.87e-05	0.00053	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	6.87e-05	0.00053	CcSEcCtD
Gefitinib—Rash—Alitretinoin—peripheral nervous system neoplasm	6.83e-05	0.000527	CcSEcCtD
Gefitinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	6.82e-05	0.000526	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	6.81e-05	0.000526	CcSEcCtD
Gefitinib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	6.8e-05	0.000524	CcSEcCtD
Gefitinib—Urticaria—Etoposide—peripheral nervous system neoplasm	6.71e-05	0.000518	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	6.7e-05	0.000517	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	6.7e-05	0.000517	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	6.68e-05	0.000515	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	6.68e-05	0.000515	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	6.68e-05	0.000515	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	6.67e-05	0.000514	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	6.67e-05	0.000514	CcSEcCtD
Gefitinib—Vomiting—Vincristine—peripheral nervous system neoplasm	6.63e-05	0.000512	CcSEcCtD
Gefitinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	6.62e-05	0.000511	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	6.58e-05	0.000508	CcSEcCtD
Gefitinib—Rash—Vincristine—peripheral nervous system neoplasm	6.58e-05	0.000507	CcSEcCtD
Gefitinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	6.57e-05	0.000507	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	6.57e-05	0.000507	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	6.55e-05	0.000506	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	6.54e-05	0.000504	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	6.5e-05	0.000501	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	6.48e-05	0.0005	CcSEcCtD
Gefitinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	6.43e-05	0.000496	CcSEcCtD
Gefitinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	6.31e-05	0.000487	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	6.3e-05	0.000486	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	6.23e-05	0.000481	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	6.23e-05	0.00048	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	6.2e-05	0.000478	CcSEcCtD
Gefitinib—Nausea—Vincristine—peripheral nervous system neoplasm	6.2e-05	0.000478	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	6.19e-05	0.000477	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	6.17e-05	0.000476	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	6.17e-05	0.000476	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	6.09e-05	0.00047	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	6.08e-05	0.000469	CcSEcCtD
Gefitinib—Asthenia—Etoposide—peripheral nervous system neoplasm	6.06e-05	0.000468	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	6.05e-05	0.000467	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	6.05e-05	0.000467	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.01e-05	0.000464	CcSEcCtD
Gefitinib—Pruritus—Etoposide—peripheral nervous system neoplasm	5.98e-05	0.000461	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	5.96e-05	0.00046	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	5.89e-05	0.000455	CcSEcCtD
Gefitinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	5.87e-05	0.000452	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.00045	CcSEcCtD
Gefitinib—Rash—Cisplatin—peripheral nervous system neoplasm	5.82e-05	0.000449	CcSEcCtD
Gefitinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	5.81e-05	0.000448	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	5.8e-05	0.000448	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	5.78e-05	0.000446	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000445	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	5.73e-05	0.000442	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	5.6e-05	0.000432	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.56e-05	0.000429	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	5.51e-05	0.000425	CcSEcCtD
Gefitinib—Nausea—Cisplatin—peripheral nervous system neoplasm	5.48e-05	0.000423	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000421	CcSEcCtD
Gefitinib—Vomiting—Etoposide—peripheral nervous system neoplasm	5.37e-05	0.000415	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	5.37e-05	0.000414	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000414	CcSEcCtD
Gefitinib—Rash—Etoposide—peripheral nervous system neoplasm	5.33e-05	0.000411	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	5.32e-05	0.000411	CcSEcCtD
Gefitinib—Malaise—Epirubicin—peripheral nervous system neoplasm	5.23e-05	0.000404	CcSEcCtD
Gefitinib—Cough—Epirubicin—peripheral nervous system neoplasm	5.07e-05	0.000391	CcSEcCtD
Gefitinib—CYP2D6—brainstem—peripheral nervous system neoplasm	5.06e-05	0.0116	CbGeAlD
Gefitinib—Nausea—Etoposide—peripheral nervous system neoplasm	5.02e-05	0.000387	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000383	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	4.91e-05	0.000379	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—peripheral nervous system neoplasm	4.84e-05	0.000374	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.000373	CcSEcCtD
Gefitinib—Infection—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000363	CcSEcCtD
Gefitinib—Cough—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.000362	CcSEcCtD
Gefitinib—Shock—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.00036	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	4.65e-05	0.000358	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	4.64e-05	0.000358	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000355	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.54e-05	0.00035	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—peripheral nervous system neoplasm	4.52e-05	0.000348	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000345	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000341	CcSEcCtD
Gefitinib—Infection—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000336	CcSEcCtD
Gefitinib—Shock—Doxorubicin—peripheral nervous system neoplasm	4.31e-05	0.000333	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.3e-05	0.000332	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	4.29e-05	0.000331	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.000328	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000326	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.000322	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000318	CcSEcCtD
Gefitinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	4.11e-05	0.00945	CbGeAlD
Gefitinib—Hypotension—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000316	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.09e-05	0.000316	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000315	CcSEcCtD
Gefitinib—Pain—Epirubicin—peripheral nervous system neoplasm	4.05e-05	0.000313	CcSEcCtD
Gefitinib—Constipation—Epirubicin—peripheral nervous system neoplasm	4.05e-05	0.000313	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000301	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.87e-05	0.000299	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.000294	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000292	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000292	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.76e-05	0.00029	CcSEcCtD
Gefitinib—Pain—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000289	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000289	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.000289	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.000289	CcSEcCtD
Gefitinib—ABCG2—cerebellum—peripheral nervous system neoplasm	3.64e-05	0.00836	CbGeAlD
Gefitinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.000277	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	3.49e-05	0.000269	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	3.48e-05	0.000269	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000267	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000267	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.4e-05	0.000262	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.35e-05	0.000259	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.24e-05	0.00025	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.23e-05	0.000249	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000243	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.1e-05	0.000239	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.000232	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000231	CcSEcCtD
Gefitinib—Rash—Epirubicin—peripheral nervous system neoplasm	2.99e-05	0.00023	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.98e-05	0.00023	CcSEcCtD
Gefitinib—Nausea—Epirubicin—peripheral nervous system neoplasm	2.81e-05	0.000217	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000215	CcSEcCtD
Gefitinib—Rash—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.000213	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.000213	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.6e-05	0.000201	CcSEcCtD
Gefitinib—CYP2D6—cerebellum—peripheral nervous system neoplasm	2.49e-05	0.00573	CbGeAlD
Gefitinib—ABCB1—cerebellum—peripheral nervous system neoplasm	1.79e-05	0.00412	CbGeAlD
Gefitinib—CYP1A1—Metabolism—GNS—peripheral nervous system neoplasm	1.4e-05	0.000213	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.39e-05	0.000212	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—ERBB2—peripheral nervous system neoplasm	1.39e-05	0.000212	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFNB1—peripheral nervous system neoplasm	1.39e-05	0.000211	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.37e-05	0.000208	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	1.36e-05	0.000208	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.35e-05	0.000206	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	1.34e-05	0.000205	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—ERBB2—peripheral nervous system neoplasm	1.34e-05	0.000204	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.34e-05	0.000204	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000204	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000204	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000204	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NME1—peripheral nervous system neoplasm	1.34e-05	0.000204	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.33e-05	0.000202	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	1.33e-05	0.000202	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.33e-05	0.000202	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	1.32e-05	0.0002	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.31e-05	0.0002	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NRAS—peripheral nervous system neoplasm	1.31e-05	0.0002	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	1.31e-05	0.000199	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.3e-05	0.000199	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.3e-05	0.000198	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.29e-05	0.000197	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTPN11—peripheral nervous system neoplasm	1.29e-05	0.000197	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.29e-05	0.000197	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	1.29e-05	0.000196	CbGpPWpGaD
Gefitinib—EGFR—Disease—SLC2A1—peripheral nervous system neoplasm	1.29e-05	0.000196	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	1.29e-05	0.000196	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—NRAS—peripheral nervous system neoplasm	1.28e-05	0.000195	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GNS—peripheral nervous system neoplasm	1.27e-05	0.000194	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—AKT1—peripheral nervous system neoplasm	1.27e-05	0.000193	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.26e-05	0.000192	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	1.25e-05	0.00019	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.24e-05	0.000189	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.24e-05	0.000189	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	1.23e-05	0.000188	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.23e-05	0.000187	CbGpPWpGaD
Gefitinib—MKNK1—Disease—MYC—peripheral nervous system neoplasm	1.22e-05	0.000186	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NME1—peripheral nervous system neoplasm	1.22e-05	0.000186	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.21e-05	0.000184	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.21e-05	0.000183	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—ERBB2—peripheral nervous system neoplasm	1.2e-05	0.000183	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.2e-05	0.000182	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.19e-05	0.000181	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.19e-05	0.000181	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.18e-05	0.00018	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	1.18e-05	0.000179	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.18e-05	0.000179	CbGpPWpGaD
Gefitinib—ALB—Metabolism—COX2—peripheral nervous system neoplasm	1.18e-05	0.000179	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.17e-05	0.000179	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PTPN11—peripheral nervous system neoplasm	1.17e-05	0.000178	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.16e-05	0.000177	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	1.14e-05	0.000174	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.12e-05	0.00017	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—ERBB2—peripheral nervous system neoplasm	1.11e-05	0.000169	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.1e-05	0.000167	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	1.1e-05	0.000167	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.09e-05	0.000165	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HGF—peripheral nervous system neoplasm	1.07e-05	0.000163	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.07e-05	0.000163	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.07e-05	0.000163	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.06e-05	0.000161	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.06e-05	0.000161	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NRAS—peripheral nervous system neoplasm	1.06e-05	0.000161	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	1.06e-05	0.000161	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	1.06e-05	0.000161	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.05e-05	0.00016	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.05e-05	0.00016	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.04e-05	0.000159	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.03e-05	0.000157	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.03e-05	0.000157	CbGpPWpGaD
Gefitinib—ERBB3—Disease—ERBB2—peripheral nervous system neoplasm	1.02e-05	0.000156	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NRAS—peripheral nervous system neoplasm	1.02e-05	0.000155	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.02e-05	0.000155	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.02e-05	0.000155	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.01e-05	0.000153	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.01e-05	0.000153	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	9.99e-06	0.000152	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	9.93e-06	0.000151	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	9.71e-06	0.000148	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	9.7e-06	0.000148	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	9.62e-06	0.000146	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HRAS—peripheral nervous system neoplasm	9.61e-06	0.000146	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MYC—peripheral nervous system neoplasm	9.52e-06	0.000145	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	9.51e-06	0.000145	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.41e-06	0.000143	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.4e-06	0.000143	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	9.36e-06	0.000142	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—HRAS—peripheral nervous system neoplasm	9.36e-06	0.000142	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—AKT1—peripheral nervous system neoplasm	9.35e-06	0.000142	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ERBB2—peripheral nervous system neoplasm	9.23e-06	0.00014	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.2e-06	0.00014	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	9.18e-06	0.00014	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	9.13e-06	0.000139	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—NRAS—peripheral nervous system neoplasm	9.13e-06	0.000139	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.07e-06	0.000138	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	8.98e-06	0.000137	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	8.96e-06	0.000136	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.82e-06	0.000134	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	8.58e-06	0.000131	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.57e-06	0.00013	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	8.54e-06	0.00013	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.54e-06	0.00013	CbGpPWpGaD
Gefitinib—MKNK1—Disease—AKT1—peripheral nervous system neoplasm	8.49e-06	0.000129	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	8.46e-06	0.000129	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NRAS—peripheral nervous system neoplasm	8.43e-06	0.000128	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.31e-06	0.000126	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	8.11e-06	0.000123	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NRAS—peripheral nervous system neoplasm	8.06e-06	0.000123	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	7.96e-06	0.000121	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.92e-06	0.00012	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTPN11—peripheral nervous system neoplasm	7.81e-06	0.000119	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.79e-06	0.000118	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NRAS—peripheral nervous system neoplasm	7.78e-06	0.000118	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	7.74e-06	0.000118	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—peripheral nervous system neoplasm	7.74e-06	0.000118	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	7.72e-06	0.000117	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	7.57e-06	0.000115	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.55e-06	0.000115	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	7.54e-06	0.000115	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—peripheral nervous system neoplasm	7.47e-06	0.000114	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.43e-06	0.000113	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.26e-06	0.000111	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MYC—peripheral nervous system neoplasm	7.25e-06	0.00011	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.22e-06	0.00011	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTPN11—peripheral nervous system neoplasm	7.21e-06	0.00011	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.17e-06	0.000109	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.15e-06	0.000109	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	7.15e-06	0.000109	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	7.12e-06	0.000108	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.04e-06	0.000107	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NRAS—peripheral nervous system neoplasm	7.02e-06	0.000107	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	6.93e-06	0.000105	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	6.87e-06	0.000105	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AKT1—peripheral nervous system neoplasm	6.83e-06	0.000104	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.82e-06	0.000104	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	6.76e-06	0.000103	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.75e-06	0.000103	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.73e-06	0.000102	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	6.72e-06	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—peripheral nervous system neoplasm	6.68e-06	0.000102	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.66e-06	0.000101	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKT1—peripheral nervous system neoplasm	6.6e-06	0.0001	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	6.59e-06	0.0001	CbGpPWpGaD
Gefitinib—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	6.52e-06	9.92e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.5e-06	9.9e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	6.46e-06	9.84e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	6.37e-06	9.7e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.36e-06	9.68e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	6.34e-06	9.66e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	6.32e-06	9.61e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.22e-06	9.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERBB2—peripheral nervous system neoplasm	6.17e-06	9.39e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—peripheral nervous system neoplasm	6.17e-06	9.39e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TH—peripheral nervous system neoplasm	6.13e-06	9.33e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.97e-06	9.08e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.94e-06	9.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.9e-06	8.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.89e-06	8.97e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	5.85e-06	8.91e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	5.81e-06	8.84e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	5.71e-06	8.69e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	5.7e-06	8.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB2—peripheral nervous system neoplasm	5.7e-06	8.67e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—peripheral nervous system neoplasm	5.7e-06	8.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.66e-06	8.62e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.66e-06	8.61e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.58e-06	8.5e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	5.5e-06	8.37e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	5.49e-06	8.35e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.47e-06	8.33e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.45e-06	8.3e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.45e-06	8.29e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—peripheral nervous system neoplasm	5.45e-06	8.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.41e-06	8.24e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	5.39e-06	8.2e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	5.38e-06	8.19e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	5.37e-06	8.17e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	5.34e-06	8.12e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.27e-06	8.02e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.23e-06	7.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.21e-06	7.92e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	5.16e-06	7.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.14e-06	7.82e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—peripheral nervous system neoplasm	5.14e-06	7.82e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.13e-06	7.82e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.09e-06	7.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.08e-06	7.73e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	5.06e-06	7.7e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.05e-06	7.68e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—peripheral nervous system neoplasm	5.03e-06	7.65e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	5.02e-06	7.64e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	5e-06	7.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5e-06	7.61e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	4.91e-06	7.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—peripheral nervous system neoplasm	4.69e-06	7.14e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.62e-06	7.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.54e-06	6.91e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—peripheral nervous system neoplasm	4.53e-06	6.9e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	4.49e-06	6.84e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	4.41e-06	6.71e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	4.38e-06	6.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—peripheral nervous system neoplasm	4.33e-06	6.6e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.33e-06	6.58e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.23e-06	6.43e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.17e-06	6.35e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	4.17e-06	6.34e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.14e-06	6.3e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	4.13e-06	6.29e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	4.1e-06	6.23e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.05e-06	6.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—peripheral nervous system neoplasm	4.04e-06	6.14e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	4.02e-06	6.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.99e-06	6.07e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.99e-06	6.07e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	3.94e-06	6e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	3.77e-06	5.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.76e-06	5.72e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.65e-06	5.56e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.62e-06	5.51e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.52e-06	5.36e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	3.52e-06	5.36e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.47e-06	5.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—peripheral nervous system neoplasm	3.43e-06	5.23e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.36e-06	5.11e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	3.33e-06	5.07e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.32e-06	5.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.32e-06	5.05e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	3.31e-06	5.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—peripheral nervous system neoplasm	3.17e-06	4.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.03e-06	4.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—peripheral nervous system neoplasm	3.03e-06	4.61e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.93e-06	4.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.83e-06	4.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—peripheral nervous system neoplasm	2.8e-06	4.26e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.7e-06	4.11e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.65e-06	4.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.32e-06	3.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.22e-06	3.38e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.19e-06	3.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.96e-06	2.98e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	1.57e-06	2.39e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.48e-06	2.25e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	1.35e-06	2.06e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	1.21e-06	1.85e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.18e-06	1.8e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.12e-06	1.7e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.11e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	7.29e-07	1.11e-05	CbGpPWpGaD
